Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 276Lymphoid 230Other hematologic neoplasm 202Myeloid 107CNS 59Sarcoma 46Classical hematology 40Dermatologic 38Gastrointestinal 19Other solid neoplasm 16Breast 15Genitourinary 13Gynecologic 12Other neoplasm 5Other 2Endocrine 2Thoracic 1

Conditions

Mucositis 2Multiple Myeloma 1Leukemia 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Exercise 28Metformin 24Surveys and Questionnaires 19Radiotherapy 14Methods 14Early Intervention, Educational 13Counseling 13Educational Status 12naloxegol 10Standard of Care 10Tirzepatide 9Nutrition Assessment 9Diet Therapy 9Cisplatin 9Resistance Training 8Psychiatric Rehabilitation 8Diet 8Therapeutics 7Interviews as Topic 7alvimopan 6Liraglutide 6Fibroblast Growth Factor 7 6Caloric Restriction 6semaglutide 5Radiation 5Low-Level Light Therapy 5Injections 5Exenatide 5Diet, Mediterranean 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melphalan × Other × Clear all
NCT01085617 2025-03-30

UKALL14

University College, London

Completed
OtherOther hematologic neoplasm

Leukemia, Mucositis

NCT00482846 2014-04-15

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
38 enrolled
OtherPlasma cell

Multiple Myeloma, Mucositis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡